Generated by AI
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell- and exosome-based therapies for rare diseases with significant unmet medical needs. Its leading program, deramiocel, is an allogeneic cardiac-derived cell therapy designed to address skeletal and cardiac muscle complications associated with Duchenne muscular dystrophy. The company’s research focuses on cardiosphere-derived cells with immunomodulatory and antifibrotic properties, supporting therapeutic development in muscular and cardiovascular disorders. Capricor Therapeutics, Inc. also operates the StealthX exosome platform, which uses engineered exosomes for vaccine development and the delivery of biological payloads such as proteins, oligonucleotides, and small molecules. Its broader pipeline includes additional exosome-based therapeutic and vaccine programs. Through these platforms, the company occupies a specialized position within the biotechnology market, combining regenerative medicine, advanced drug delivery, rare-disease therapeutics, and cell-based treatment development.
Website10865 Road to the Cure
San Diego, CA, 92121
United States
The latest articles about CAPR.
Regenxbio (RGNX) stock and Capricor Therapeutics (CAPR) stock rise as the White House pulls President Trump's pick to lead the FDA. Read more here.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 19's posts. Generated by AI.
Investors talking about CAPR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.